Hostname: page-component-5db58dd55d-m58mf Total loading time: 0 Render date: 2026-05-27T04:53:36.839Z Has data issue: false hasContentIssue false
  • English
  • Français

Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma

Published online by Cambridge University Press:  29 June 2007

John S. Rubin ,
Scott Wadler ,
Jonathan J. Baitler ,
Hilda Haynes ,
Alla Rozenblet ,
Frances McGill ,
Gary Goldberg  and
Carolyn Runowicz
John S. Rubin*
Affiliation:
Department of Otolaryngolog, Lewish Hospital NHS Trust, Lewisham High Street, London, UK.
Scott Wadler
Affiliation:
Departments of Oncology, Montefiore Medical Center, Bronx, New York.
Jonathan J. Baitler
Affiliation:
Departments of Radiation Oncology, Montefiore Medical Center, Bronx, New York.
Hilda Haynes
Affiliation:
Departments of Oncology, Montefiore Medical Center, Bronx, New York.
Alla Rozenblet
Affiliation:
Departments of Radiology, Montefiore Medical Center, Bronx, New York.
Frances McGill
Affiliation:
Department of Onstetrics and Gynecology, Albert Einstein College of Medicine, Bronx, New York, USA.
Gary Goldberg
Affiliation:
Department of Onstetrics and Gynecology, Albert Einstein College of Medicine, Bronx, New York, USA.
Carolyn Runowicz
Affiliation:
Department of Onstetrics and Gynecology, Albert Einstein College of Medicine, Bronx, New York, USA.
*
Mr J. S. Rubin, M.D., F.A.C.S., ENT Directorate. Lewisham Hospital NHS Trust, Lewisham High Street, London SE13 6LH
Get access Rights & Permissions [Opens in a new window]

Abstract

WR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin. which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma. 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes. predominantly in the high frequencies. There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.

Keywords

CisplatinOtotoxicityHearing loss, sensorineuralAudiometry

Information

Type
Short Communications
Information
The Journal of Laryngology & Otology , Volume 109 , Issue 8 , August 1995 , pp. 744 - 747
Copyright
Copyright © JLO (1984) Limited 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Aguilar-Markulis, N. V., Beckley, S., Priore, R., Mettlin, C. (1981) Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. Journal of Surgical Oncology 16: 111–123.CrossRefGoogle ScholarPubMed
Calabro-Jones, P. M., Fahey, R. C., Smoluk, G. D., Ward, J. F. (1985) Alkaline phosphatase promotes radioprotection and accumulation of WR 1065 in V79–171 cells incubated in medium containing WR 2721. International Journal of Radiation Biology 47: 23–27.Google ScholarPubMed
Calabro-Jones, P. M., Aguilera, J. A., Ward, J. F.Smoluk, G. D., Fahey, R. C. (1988) Uptake of WR 2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Research 48: 3634–3640.Google ScholarPubMed
Fleming, S., Peppard, S., Ratanatharathorn, V., Schumacher, M., Weaver, A., Al-Sarraf, M., Peters, G. (1985) Ototoxicity from cis-platinum in patients with stages III and IV previously untreated squamous cell cancer of the head and neck. Amercian Journal of Clinical Oncology 8: 302–306.CrossRefGoogle ScholarPubMed
Gandara, D. R., Perez, E. A., Wiebe, V., De Gregorio, M. W. (1991) Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Seminars in Oncology 18(suppl 3): 49–55.Google ScholarPubMed
Glick, J., Kemp, G., Rose, P., McCulloch, W., Scheffler, B., Schein, P. (1992) A randomized trial of cyclophosphamide and cisplatin ± WR 2721 in the treatment of advanced epithelial ovarian cancer. Proceedings of the American Society of Clinical Oncology 11: 109.Google Scholar
Glover, D., Glick, J. H., Weiler, C., Fox, K., Guerry, D. (1987) WR 2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. Journal of Clinical Oncology 5: 574–578.CrossRefGoogle ScholarPubMed
Glover, D., Grabelsky, S., Fox, K., Weiler, C., Cannon, L., Glick, J. (1989) Clinical trails of WR 2721 and cis–platinum. Radiation Oncology, Biology and Physics 16: 1201–1204.CrossRefGoogle Scholar
Helson, L., Okonkwo, E., Anton, L., Cvitkovic, E. (1978) Cis-Platinum ototoxicity. Clinical Toxicology 13: 469–478.CrossRefGoogle ScholarPubMed
Kemp, G. M., Glover, D. J., Schein, P. S. (1990) The role of WR 2721 in the reduction of combined cisplatin and cyclophosphamide toxicity. Proceedings of the American Society of Clinical Oncology 9: 67 (abstract 259).Google Scholar
Kopelman, J., Budnick, A. S., Sessions, R. B., Kramer, M. B., Wong, G. Y. (1988) Ototoxicity of high dose cisplatin b bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 98: 858–864.CrossRefGoogle Scholar
Laurell, G., Borg, E. (1988) Ototoxicity of cisplatin in gynaecological cancer patients. Scandinavian Audiology (Copenhagen) 17: 241–247.CrossRefGoogle ScholarPubMed
Laurell, G., Jungnelius, U. (1990) High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 100: 724–734.CrossRefGoogle ScholarPubMed
Mahoney, D. H., Weaver, T., Steuber, C. P., Starling, K. A. (1983) Ototoxicity with cisplatin therapy. Journal of Pediatrics 103: 1006.CrossRefGoogle ScholarPubMed
McHaney, V. A., Thibadoux, G., Hayes, F A., Green, A. A. (1983) Hearing loss in children receiving cisplatin chemotherapy. Journal of Pediatrics 102: 314–317.CrossRefGoogle ScholarPubMed
Melamed, L. B., Selim, M. A.Schuchman, D. (1985) Cisplatin ototoxicity in gynecological cancer patients. Cancer 55: 41–43.3.0.CO;2-N>CrossRefGoogle Scholar
Mollman, J. F., Glover, D. J., Hogan, W. M., Furman, R. E. (1988) Risk factors, prognosis and protection by WR 2721. Cancer 61: 2192–2195.3.0.CO;2-A>CrossRefGoogle ScholarPubMed
Moroso, M. J., Blair, R. L. (1983) A review of cis-platinum ototoxicity. Journal Of Otolaryngology 12: 365–369.Google ScholarPubMed
Nakai, Y., Konishi, K., Chang, K. C., Ohashi, K., Morisaki, N., Minowa, Y., Morimoto, A. (1982) Ototoxicity of the anticancer drug cisplatin: an experimental study. Acta otolaryngologica (Stockholm) 93: 227–232.CrossRefGoogle ScholarPubMed
Piel, I. J., Meyer, D., Perlia, C. P., Wolfe, V. I. (1974) Effects of cis-diamminedichloroplatinum (NSC-1 19875) on hearing function in man. Cancer Chemotherapy Reports 58: 871–875.Google Scholar
Reddel, R. R., Kefford, R. F., Grant, J. M., Coates, A. S., Fox, R. M., Tattersall, M. H. N. (1982) Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treatment Reports 66: 19–23.Google ScholarPubMed
Schaefer, S. D., Post, J. D., Close, L. G., Wright, C. G. (1985) Ototoxicity of low- and moderate-dose cisplatin. Cancer 56: 1934–1939.3.0.CO;2-F>CrossRefGoogle ScholarPubMed
Treskes, M., Boven, E., Holwerda, U., Pinedo, H. M., van der Vijgh, W. J. F. (1992a) Time-dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR 2721 in the mouse. Cancer Research 42: 2257–2260.Google Scholar
Treskes, M., Nijtmans, L. G. J., Fichtinger-Schepman, A. M. J., van der Vijgh, W. J. F. (1992b) Effects of the modulating agent WR 2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosuiphate and diethyldithiocarbamate. Biochemical Pharmacology 43: 1013–1019.CrossRefGoogle Scholar
Vermorken, J. B., Kapteijn, T. S., Hart, A. A. M., Pinedo, H. M. (1983) Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. European Journal of Cancer Clinical Oncology 19: 53–58.CrossRefGoogle ScholarPubMed
Vodvarka, P., Foukalova, J., Mrazek, J., Philippova, J. (1985) Ototoxicity of cis-diamminedichioroplatinum. Neoplasma 32: 229–238.Google Scholar
Wadler, S., Beitler, J. J., Rubin, J. S., Haynes, H., McGill, F, Rosenblit, A., Goldberg, G., Cohen, C., Speyer, J., Runowicz, C. (1993) A pilot clinical trail trial of cisplatin, radiation therapy and the chemoprotective agent, WR 2721, against carcinoma of the uterine cervix: a New York gynecological oncology group study. Journal of Clinical Oncology 11: 1511–1516.CrossRefGoogle Scholar
Weatherly, R. A., Owens, J. J., Catlin, F. I.Mahoney, D. H. (1991) Cis-platinum ototoxicity in children. Larynoscope 101: 917–924.CrossRefGoogle ScholarPubMed
Yuhas, J. M., Culo, F. (1980) Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (11) by WR 2721 without altering its antitumor properties. Cancer Treatment Reports 64: 57–64.Google Scholar
Yuhas, J. M., Speilman, J. M., Culo, F. (1980a) The role of WR 2721 in radiotherapy and/or chemotherapy. Cancer Clinical Trials 3: 211–216.Google ScholarPubMed
Yuhas, J. M., Spellman, J. M., Jordan, S. W., Pardini, M. C., Afzal, S. M. J., Culo, F. (1980b) Treatment of tumours with the combination of WR 2721 and cis-dichlorodiammineplatinum (II) or cycbophosphamide. British Journal of Cancer 42: 574–585.CrossRefGoogle ScholarPubMed